Medpage Today on MSN12d
Novel Drug Improved Symptoms in Eosinophilic Esophagitis
The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...
Future Market Insights2h
Global Esophageal Catheters Market Set for Strong Growth, Expected to Reach USD 4.5 Billion by 2032
Esophageal Catheters Market. The global esophageal catheters market is poised for significant expansion, with a projected market value of USD 2.2 billion in 2022, and a robust com ...
Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
People on MSN3d
Virginia Congressman Reveals New Esophageal Cancer Diagnosis 2 Days After Winning Reelection
"Cancer can be tough. But so am I," Democratic Rep. Gerry Connolly said. "I will attack this the only way I know how – with ...
Pharmabiz4d
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
Research explores non-invasive diagnosis for Barrett's esophagus
New research is exploring low-cost, non-invasive ways to diagnose Barrett's esophagus, a condition associated with deadly ...
Augusta Free Press2d
Virginia Congressman Gerry Connolly shares diagnosis of esophageal cancer
has been diagnosed with esophageal cancer. Connolly, as reported by The Washington Post, said Thursday morning he will ...
The Globe and Mail13d
Eosinophilic Esophagitis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis. IRL201104, is ...
Daily4d
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
PharmiWeb11d
Global Esophageal Implant Market Poised for Strong Growth, Expected to Surpass USD 280 Million by 2033 at a 6.7% of CAGR
Esophageal Implant MarketThe global esophageal implant market is set for substantial growth, with its valuation projected to reach USD 147 million in 2023. Over the next decade, the market is ...
Morningstar5d
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Sanofi “Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing standard of care treatment options, and, as a result, many of these young patients ...